Acute Pain

24
Pipeline Programs
6
Companies
19
Clinical Trials
6
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
6
0
6
9
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 18 programs with unclassified modality

On Market (6)

Approved therapies currently available

Pfizer
BEXTRAApproved
valdecoxib
Pfizer
oral2001
U
DICLOFENACApproved
diclofenac
Unknown Company
oral
U
DICLOFENAC SODIUMApproved
diclofenac
Unknown Company
topical2022
VP
JOURNAVXApproved
suzetrigine
Vertex Pharmaceuticals
Sodium Channel Blocker [EPC]oral2025
Trevena
OLINVYKApproved
oliceridine
Trevena
intravenous2020
U
ZORVOLEXApproved
diclofenac
Unknown Company
oral2013

Competitive Landscape

5 companies ranked by most advanced pipeline stage

VP
10 programs
1
5
2
2
SuzetriginePhase 41 trial
SuzetriginePhase 41 trial
SUZPhase 31 trial
SuzetriginePhase 31 trial
VX-150Phase 21 trial
+5 more programs
Active Trials
NCT05347394Completed100Est. Apr 2023
NCT03764072Completed250Est. Jan 2019
NCT03206749Completed243Est. Dec 2017
+7 more trials
Trevena
TrevenaPA - Chesterbrook
4 programs
1
3
1
OLINVYK(Oliceridine)Phase 31 trial
OliceridinePhase 31 trial
TRV130Phase 31 trial
TRV130Phase 21 trial
Active Trials
NCT02100748Completed333Est. Oct 2014
NCT02815709Completed418Est. Jan 2017
NCT02820324Completed407Est. Jan 2017
+1 more trials
Pfizer
PfizerNEW YORK, NY
2 programs
1
1
valdecoxibPhase 4Small Molecule1 trial
PF-04457845, FAAH inhibitorPhase 11 trial
Active Trials
NCT00836082Completed41Est. Jul 2009
NCT00657449Terminated45Est. Oct 2004
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
2 programs
1
DiclofenacPhase 31 trial
Hyoscine n-butylbromideN/A1 trial
Active Trials
NCT02910167Completed360Est. Feb 2017
NCT02700815Completed746Est. Jul 2017
BioLineRx
BioLineRxIsrael - Modi’in
1 program
1
MorphinePhase 1/21 trial
Active Trials
NCT00374881CompletedEst. Aug 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Vertex PharmaceuticalsSuzetrigine
Vertex PharmaceuticalsSuzetrigine
Pfizervaldecoxib
Vertex PharmaceuticalsSuzetrigine
Vertex PharmaceuticalsSUZ
Boehringer IngelheimDiclofenac
TrevenaOliceridine
TrevenaOliceridine
TrevenaTRV130
Vertex PharmaceuticalsVX-993
Vertex PharmaceuticalsVX-548
Vertex PharmaceuticalsVX-548
Vertex PharmaceuticalsVX-150
Vertex PharmaceuticalsVX-150
TrevenaTRV130

Showing 15 of 19 trials with date data

Clinical Trials (19)

Total enrollment: 6,995 patients across 19 trials

NCT06887959Vertex PharmaceuticalsSuzetrigine

A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries

Start: Mar 2025Est. completion: Nov 202547 patients
Phase 4Completed
NCT06887972Vertex PharmaceuticalsSuzetrigine

A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries

Start: Mar 2025Est. completion: Nov 2025100 patients
Phase 4Completed
NCT00657449Pfizervaldecoxib

A Double-blind, Double-dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain

Start: Jun 2003Est. completion: Oct 200445 patients
Phase 4Terminated
NCT05558410Vertex PharmaceuticalsSuzetrigine

Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty

Start: Oct 2022Est. completion: Sep 20231,118 patients
Phase 3Completed
NCT05553366Vertex PharmaceuticalsSUZ

Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy

Start: Oct 2022Est. completion: Dec 20231,075 patients
Phase 3Completed
NCT02700815Boehringer IngelheimDiclofenac

Capsaicin + Diclofenac Gel in Acute Back Pain or Neck Pain

Start: May 2016Est. completion: Jul 2017746 patients
Phase 3Completed
NCT02815709TrevenaOliceridine

Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy

Start: May 2016Est. completion: Jan 2017418 patients
Phase 3Completed
NCT02820324TrevenaOliceridine

Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty

Start: May 2016Est. completion: Jan 2017407 patients
Phase 3Completed
NCT02656875TrevenaTRV130

A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain

Start: Dec 2015Est. completion: Aug 2017768 patients
Phase 3Completed
NCT06619847Vertex PharmaceuticalsVX-993

A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy

Start: Oct 2024Est. completion: May 2025367 patients
Phase 2Completed
NCT05034952Vertex PharmaceuticalsVX-548

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty

Start: Aug 2021Est. completion: Dec 2021303 patients
Phase 2Completed
NCT04977336Vertex PharmaceuticalsVX-548

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy

Start: Jul 2021Est. completion: Mar 2022274 patients
Phase 2Completed
NCT03764072Vertex PharmaceuticalsVX-150

A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

Start: Dec 2018Est. completion: Jan 2019250 patients
Phase 2Completed
NCT03206749Vertex PharmaceuticalsVX-150

A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

Start: Jun 2017Est. completion: Dec 2017243 patients
Phase 2Completed
NCT02100748TrevenaTRV130

A Study of TRV130 for the Treatment of Pain After Bunionectomy

Start: Apr 2014Est. completion: Oct 2014333 patients
Phase 2Completed
NCT00374881BioLineRxMorphine

A Study of the Safety and Efficacy of Combination Therapy With Morphine, Phenylephrine and Sorbitol in Human Subjects

Start: Sep 2006Est. completion: Aug 2007
Phase 1/2Completed
NCT05347394Vertex PharmaceuticalsVX-708

A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants

Start: Apr 2022Est. completion: Apr 2023100 patients
Phase 1Completed
NCT00836082PfizerPF-04457845, FAAH inhibitor

A Multiple Dose Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04457845 in Healthy Volunteers

Start: Feb 2009Est. completion: Jul 200941 patients
Phase 1Completed
NCT02910167Boehringer IngelheimHyoscine n-butylbromide

Observational Prospective Study to Evaluate AEs, Risk Factors and Drug Utilization of BUSCAPINA COMPOSITUM N in Adults From Metropolitan Lima

Start: Oct 2016Est. completion: Feb 2017360 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs — potential near-term approvals
6 companies competing in this space